Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide

ABSTRACT Introduction Opaganib is a first‐in‐class oral sphingolipid metabolism inhibitor that inhibits sphingosinekinase 2 (SphK2) and dihydroceramide desaturase (DES) and that has a demonstrated safety and preliminary anti‐cancer activity signal in a Phase I study. Methods In this phase II trial,...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jacqueline T. Brown, Bassel Nazha, Anna C. Ferreira, Kent Armeson, Elizabeth G. Hill, Besim Ogretmen, Shikhar Mehrotra, Alan Brisendine, George Magrath, Terry F. Plasse, Theodore Stewart Gourdin, Omer Kucuk, Michael Lilly
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2026-04-01
Reeks:	Cancer Medicine
Onderwerpen:	abiraterone enzalutamide opaganib prostate cancer sphingolipid
Online toegang:	https://doi.org/10.1002/cam4.71633
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!